《异动股》永泰生物(06978.HK)逆市续涨逾13%屡创上市新高
永泰生物-B(06978.HK)连续第二天创上市新高,最高见21.75元,现造21.1元,续涨逾13%,成交进一步增至598万股,涉资1.228亿元。
永泰去年亏损按年扩大3倍至4.39亿元人民币,每股亏损0.99元人民币。永泰是内地一家领先细胞免疫治疗生物医药公司,13年来专注於T细胞免疫治疗研发和商业化,公司核心在研产品EAL是内地首款获准进入II期临床试验细胞免疫产品及当下唯一获准进入实体瘤治疗II期临床试验细胞免疫产品,该药属多靶点肿瘤细胞免疫治疗产品,并对多种癌症显示出治疗效果。该股去年7月初以每股11元来港上市,净筹约10.24亿元。挂牌後,股价曾於去年11月初反覆回落至5.8元获承接回升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.